While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

It eventually led to Still being diagnosed with ATTR amyloidosis, a rare genetic condition that causes heart problems, neuropathy, and ligament and tendon troubles. Since his diagnosis in ...

Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

misfolded versions of the protein form dangerous clumps in the heart and along nerves -- triggering a progressive and fatal disease known as transthyretin amyloidosis (ATTR). Up to a quarter of ...

Various forms of hereditary amyloidosis have been described: transthyretin (ATTR), apolipoprotein (AApo) AI, AApoAII, gelsolin, fibrinogen Aa, cystatin C and lysozyme amyloidosis. Hereditary ...

Stay ahead with the latest insights! Download DelveInsight's comprehensive Hereditary ATTR (hATTR) Amyloidosis Pipeline Report to explore emerging therapies, key Hereditary ATTR (hATTR ...

misfolded versions of the protein form dangerous clumps in the heart and along nerves-triggering a progressive and fatal disease known as transthyretin amyloidosis (ATTR). Up to a quarter of all ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...